| 摘要: |
| 目的：观察参芪补髓汤联合化疗加免疫疗法治疗气血两虚型晚期无驱动基因突变非小细胞肺癌的临床疗效。方法：将90 例气血两虚型晚期无驱动基因突变非小细胞肺癌患者随机分为治疗组和对照组，每组各45 例。对照组患者采用化疗（吉西他滨+顺铂）加信迪利单抗治疗，治疗组在对照组基础上加用参芪补髓汤治疗。治疗结束后，观察2组中医证候疗效、Karnofsky量表（KPS）评分及骨髓抑制分度（白细胞、中性粒细胞、血红蛋白、血小板下降分度）情况。结果：中医证候疗效总有效率治疗组为84.44%（38/45），对照组为57.78%（26/45），2组比较，差异有统计学意义（P＜0.05）；KPS评分治疗前后组内比较及治疗后组间比较，差异均有统计学意义（P＜0.01）；治疗后治疗组白细胞、中性粒细胞、血红蛋白、血小板下降分度情况均优于对照组（P＜0.05）。结论：参芪补髓汤联合化疗加免疫疗法治疗晚期无驱动基因突变非小细胞肺癌，能改善患者中医证候，提高生活质量，减轻骨髓抑制程度。 |
| 关键词: 参芪补髓汤 化疗 免疫疗法 气血两虚证 晚期无驱动基因突变非小细胞肺癌 |
| DOI： |
|
|
| Clinical effect of Shenqi Busui decoction in treatment of Qi-blood deficiency-type advanced non-small cell lung cancer without driver mutations：An analysis of 45 cases |
| ZHOU Bin |
| (Department of Oncology，Shaodong People’s Hospital，Shaodong 422800，Hunan，China) |
| Abstract: |
| Objective：To investigate the clinical effect of Shenqi Busui decoction combined with chemotherapy and immunotherapy in the treatment of Qi-blood deficiency-type advanced non-small cell lung cancer without driver mutations.Methods：A total of 90 patients with Qi-blood deficiency-type advanced non-small cell lung cancer without driver mutations were randomly divided into treatment group and control group，with 45 patients in each group.The patients in the control group were given chemotherapy (gemcitabine+cisplatin) combined with sintilimab，and those in the treatment group were given Shenqi Busui decoction in addition to the treatment in the control group.After treatment，the two groups were observed in terms of the treatment outcome of traditional Chinese medicine (TCM) syndrome，Karnofsky Performance Scale (KPS) score，and myelosuppression grading (the grade of reductions in leukocytes，neutrophils，hemoglobin，and platelets).Results：There was a significant difference in the overall response rate of TCM syndrome between the treatment group and the control group［84.44% (38/45) vs 57.78% (26/45)，P＜0.05］.Both groups had a significant change in KPS score after treatment，and there was a significant difference in KPS score between the two groups after treatment (P＜0.01).Compared with the control group after treatment，the treatment group had a significantly better grade of reductions in leukocytes，neutrophils，hemoglobin，and platelets (P＜0.05).Conclusion：In the treatment of Qi-blood deficiency-type advanced non-small cell lung cancer without driver mutations，Shenqi Busui decoction combined with chemotherapy and immunotherapy can improve TCM syndrome and quality of life and alleviate myelosuppression. |
| Key words: Shenqi Busui decoction chemotherapy immunotherapy Qi-blood deficiency advanced non-small cell lung cancer without driver mutations |
